References
- 1. H. Jungaberle, S. Thal, A. Zeuch, A. Rougemont-Bücking, M. von Heyden, H. Aicher and M. Scheidegger, Positive psychology in the investigation of psychedelics and entactogens: a critical review, Neuropharmacology142 (2018) 179–199; https://doi.org/10.1016/j.neuropharm.2018.06.034
- 2. D. E. Nichols, Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens, J. Psychoactive Drugs18 (1986) 305–313; https://doi.org/10.1080/02791072.1986.10472362
- 3. L. Iversen, M. White and R. Treble, Designer psychostimulants: pharmacology and differences, Neuropharmacology87 (2014) 59–65; https://doi.org/10.1016/j.neuropharm.2014.01.015
- 4. R. W. Freudenmann, F. Öxler and S. Bernschneider-Reif, The origin of MDMA (ecstasy) revisited: The true story reconstructed from the original documents, Addiction10 (2006) 1241–1245; https://doi.org//10.1111/j.1360-0443.2006.01511.x
- 5. K. S. Leung and L. B. Cottler, Ecstasy and other club drugs: a review of recent epidemiologic studies, Curr. Opin. Psychiatry. 21 (2008) 234–241; https://doi.org/10.1097/YCO.0b013e3282f9b1f1
- 6. E. Gouzoulis-Mayfrank, Differential actions of an entactogen compared to a stimulant and a hallucinogen in healthy humans, Heffter Rev. Psychodelic Res. 2 (2001) 64–72.
- 7. A. Aouidate, A. Ghaleb, M. Ghamali, S. Chtita, M. Choukrad, A. Sbai, M. Bouachrine and T. Lakhlifi, Combining DFT and QSAR studies for predicting psychotomimetic activity of substituted phenethylamines using statistical methods, J. Taibah. Univ. Sci.10 (2016) 787–796; https://doi.org/10.1016/j.jtusci.2016.07.001
- 8. M. E. Liechti, Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling, Swiss. Med. Wkly.145 (2015) w14043; https://doi.org/10.4414/smw.2015.14043
- 9. D. M. McDowell and H. D. Kleber, MDMA: its history and pharmacology, Psychiatr. Ann.24 (1994) 127–130.
- 10. A. C. Parrott, Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy, J. Psychopharmacol.19 (2005) 71–83; https://doi.org/10.1177/0269881105048900
- 11. A. C. Parrott, Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research, Hum. Psychopharmacol.28 (2013) 289–307; https://doi.org/10.1002/hup.2318
- 12. T. S. Ray, Constructing the ecstasy of MDMA from its component mental organs: Proposing the primer/probe method, Med. Hypothesis87 (2016) 48–60; https://doi.org/10.1016/j.mehy.2015.12.018
- 13. D. E. Nichols, Psychedelics, Pharmacol. Rev. 68 (2016) 264–355; https://doi.org/10.1124/pr.115.011478
- 14. F. X. Vollenweider, Brain mechanisms of hallucinogens and entactogens, Dialogues Clin Neurosci.3 (2001) 265–279.
- 15. D. Quinteros-Muñoz, P. Sáez-Briones, G. Díaz-Véliz, S. Mora-Gutiérrez, M. Rebolledo-Fuentes, and B. K. Cassels, Behavioral profiles in rats distinguish among “ecstasy”, methamphetamine and 2,5-dimethoxy-4-iodoamphetamine: Mixed effects for “ecstasy” analogues, Behav. Neurosci.124 (2010) 662–676, https://doi.org/10.1037/a0020827
- 16. A. Garcia-Romeu, B. Kersgaard and P. H. Addy, Clinical applications of hallucinogens: A Review, Exp. Clin. Psychphamacol. 24 (2016) 229–268; https://doi.org/10.1037/pha0000084
- 17. M. C. Mithoefer, M. T. Wagner, A. T. Mithoefer, L. Jerome and R. Doblin, The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment resistant posttraumatic stress disorder: the first randomized controlled pilot study, J. Psychopharmacol.25 (2010) 439–452; http://dx.doi.org/10.1177/0269881110378371
- 18. A. C. Wagner, M. C. Mithoefer, A. T. Mithoefer and C. M. Monson, Combining cognitive-behavioral conjoint therapy for PTSD with 3,4-methylenedioxymethamphetamine (MDMA): A case example, J. Psychoactive Drugs51 (2019) 166–173; https://doi.org/10.1080/02791072.2019.1589028
- 19. W. Barone, J. Beck, M. Mitsunaga-Whitten and P. Perl, Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD, J. Psychoactive Drugs51 (2019) 199–208; https://doi.org/10.1080/02791072.2019.1580805
- 20. A. L. Danforth, Embracing neurodiversity in psychedelic science: A mixed-methods inquiry into the MDMA experiences of autistic adults, J. Psychoactive Drugs51 (2019) 146–154; https://doi.org/10.1080/02791072.2019.1587116
- 21. E. Dyck, Psychedelics and dying care: A historical look at the relationship between psychedelics and palliative care, J. Psychoactive Drugs51 (2019) 102–107; https://doi.org/10.1080/02791072.2019.1581308
- 22. MDMA Investigator’s Brochure U.S. 10th Edition: 10 July 2018, https://s3-us-west-1.amazonaws.com/mapscontent/research-archive/mdma/MAPS_2018_MDMA_Investigators_Brochure_Edition10_10JUL2018.pdf.
- 23. A. P. Hall and J. A. Henry, Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management, Br. J. Anaesth.96 (2006) 678–685; https://doi.org/10.1093/bja/ael078
- 24. M. Ferigolo, A. G. da S. Machado, N. B. Oliveira and H. M. T. Barros, Ecstasy intoxication: the toxicological basis for treatment, Rev. Hosp. Clín. Fac. Med. S. Paulo58 (2003) 332–341.
- 25. M. J. Baggott, K. J. Garrison, J. R. Coyle, G. P. Galloway, A. J. Barnes, M. A. Huestis and J. E. Mendelson, Effects of the psychedelic amphetamine MDA (3,4-methylenedioxyamphetamine) in healthy volunteers, J. Psychoactive Drugs51 (2019) 108–117; https://doi.org/10.1080/02791072.2019.1593560
- 26. M. Edland-Gryt, S. Sandberg and W. Pedersen, From ecstasy to MDMA: Recreational drug use, symbolic boundaries, and drug trends, Int. J. Drug Policy5 (2017) 1–8; https://doi.org/10.1016/j.drug-po.2017.07.030
- 27. A. C. Parrott, L. A. Downey, C. A. Roberts, C. Montgomery, R. Bruno and H. C. Fox, Recreational 3,4-methylenedioxymethamphetamine or ‘ecstasy’: current perspective and future research prospects, J. Psychopharmacol.31 (2017) 959–966; https://doi.org/10.1177/0269881117711922
- 28. R. Bruno, A. J. Matthews, M. Dunn, R. Alati, F. McIlwraith, S. Hickey, L. Burns and N. Sindicich, Emerging psychoactive substance use among regular ecstasy users in Australia, Drug Alcohol Depend.124 (2012) 19–25; https://doi.org/10.1016/j.drugalcdep.2011.11.020
- 29. M. D. Krasowski, Drug-assisted Sexual Assaults: Toxicology, Fatality, and Analytical Challenge, in Critical Issues in Alcohol and Drugs of Abuse Testing (Ed. A. Dasgupta), 2nd ed., Academic Press, Elsevier Inc., London 2019, p.p. 225–236.
- 30. H. Kalant, The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs, CMAJ165 (2001) 917–928.
- 31. R. de la Torre, M. Farré, P. N. Roset, C. H. Lopez, M. Mas, J. Ortuño, E. Menoyo, N. Pizarro, J. Segura and J. Cami, Pharmacology of MDMA in humans, Ann. N. Y. Acad Sci.914 (2000) 225–937; https://doi.org/10.1111/j.1749-6632.2000.tb05199.x
- 32. S. B. Holmes, A. K. Banerjee and W. D. Alexander, Hyponatraemia and seizures after ecstasy use, Postgrad. Med. J. 75 (1999) 32–33; https://doi.org/10.1136/pgmj.75.879.32
- 33. K. A. Graeme, New drugs of abuse, Emerg. Med. Clin. North. Am. 18 (2000) 625–636; https://doi.org/10.1016/S0733-8627(05)70150-4
- 34. C. Eiden, P. Cathala, N. Fabresse, Y. Galea, J. C. Mathieu-Daude, E. Baccino and E. H. Peyrière, A case of drug-facilitated sexual assault involving 3,4-methylenedioxy-methylamphetamine, J. Psychoactive Drugs45 (2013) 94–97; https://doi.org/10.1080/02791072.2013.763573
- 35. A. L. van Nuijs, S. Castiglioni, I. Tarcomnicu, C. Postigo, M. Lopez de Alda, H. Neels, E. Zuccato, D. Barcelo and A. Covaci, Illicit drug consumption estimations derived from wastewater analysis: a critical review, Sci. Total. Environ.409 (2011) 3564–3577; https://doi.org/10.1016/j.scitotenv.2010.05.030
- 36. E. Zuccato and S. Castiglioni, Illicit drugs in the environment, Philos. Trans. A Math. Phys. Eng. Sci.367 (2009) 3965–3978; https://doi.org/10.1098/rsta.2009.0107
- 37. S. Karolack, T. Nefau, E. Bailly, A. Solgadi and Y. Levi, Estimation of illicit drugs consumption by wastewater analysis in Paris area (France), Forensic Sci. Int.200 (2010) 153–160; https://doi.org/1016/j.forsciint.2010.04.007
- 38. M. Huerta-Fontela, M. T. Galceran, J. Martin-Alonso and F. Ventura, Occurrence of psychoactive stimulatory drugs in wastewaters in north-eastern Spain, Sci. Total. Environ.397 (2008) 31–40; https://doi.org/10.1016/j.scitotenv.2008.02.057
- 39. M. S. Lowless, M. Waldman, R. Franczkiewicz and R. D. Clark, Using Chemoinformatics in Drug Discovery, in New Approaches to Drug Discovery, Handbook of Experimental Pharmacology (Eds. U. Nielsch, U. Fuhrmann, S. Jaroch), Springer, Berlin 2015, pp. 232, 139–170.
- 40. C. L. Russom, S. P. Bradbury, S. J. Broderius, D. E. Hammermeister and R. A. Drummond, Predicting modes of toxic action from chemical structure: Acute toxicity in the fathead minnow (Pimephales promelas), Environ. Toxicol.16 (1997) 948–967; https://doi.org/10.1002/etc.5620160514
- 41. H. Zhu, A. Tropsha, D. Fourches, A. Varnek, E. Papa, P. Gramatica, T. Oberg, P. Dao, A. Cherkasov and I. V. Tetko, Combinatorial QSAR modeling of chemical toxicants tested against Tetrahymena pyriformis, J. Chem. Inf. Model.48 (2008) 766–784; https://doi.org/10.1021/ci700443v
- 42. A. Golbamaki, A. Cassano, A. Lombardo, Y. Moggio, M. Colafranceschi and E. Benfenati, Comparison of in silico models for prediction of Daphnia magna acute toxicity, SAR QSAR Environ. Res.25 (2014) 673–694; https://doi.org/10.1080/1062936X.2014.923041
- 43. J. L. Hamelink and A. Spacie, Fish and chemicals: The process of accumulation, Annu. Rev. Pharmacol. Toxicol.17 (1977) 167–177; https://doi.org/10.1146/annurev.pa.17.040177.001123
- 44. Z. Zhan, L. Li, S. Tian, X. Zhen and Y. Li, Prediction of chemical biodegradability using computational methods, Mol. Simulat.43 (2017) 1277–1290; https://doi.org/10.1080/08927022.2017.1328556
- 45. J. Kirchmair, M. J. Williamson, J. D. Tyzack, L. Tan, P. J. Bond, A. Bender and Robert C. Glen, Computational prediction of metabolism: sites, products, SAR, P450. Enzyme dynamics, and mechanisms, J. Chem. Inf. Model. 52 (2012) 617–648; dx.doi.org/10.1021/ci200542m
- 46. T. T. Abraham, A. J. Barnes, R. H. Lowe, E. A. Kolbrich Spargo, G. Milman, S. O. Pirnay, D. A. Gorelick, R. S. Goodwin and M. A. Huestis, Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans, J. Anal. Toxicol.33 (2009) 439–446; https://doi.org/10.1093/jat/33.8.439
- 47. C. Burgess, A. Donohoe and M. Gill, Agony and ecstasy: a review of MDMA effects and toxicity, Eur. Psychiatry15 (2000) 287–294; https://doi.org/10.1016/S0924-9338(00)00396-5
- 48. R. L. Hartman, N. A. Desrosiers, A. J. Barnes, K. Yun, K. B. Scheidweiler, E. A. Kolbrich-Spargo, D. A. Gorelick, R. S. Goodwin and M. A. Huestis, 3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration, Anal. Bioanal. Chem. 406 (2014) 587–599; https://doi.org/10.1007/s00216-013-7468-y
- 49. F. Schifano, A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities, Psychopharmacology173 (2004) 242–248; https://doi.org/10.1007/s00213-003-1730-5
- 50. D. Trachsel, M. Hadorn and F. Baumberger, Synthesis of fluoro analogues of 3,4-(methylenedioxy) amphetamine (MDA) and its derivatives, Chem. Biodivers.3 (2006) 326–336; https://doi.org/10.1002/cbdv.200690035
- 51. R. G. Pearce, R. W. Setzer, J. L. Davis and J. F. Wambaugh, Evaluation and calibration of high-throughput predictions of chemical distribution to tissues, J. Pharmacokinet. Pharmacodyn.44 (2017) 549–565; https://doi.org/10.1007/s10928-017-9548-7
- 52. F. Cheng, Y. Ikenaga, Y. Zhou, Y. Yu, W. Li, J. Shen, Z. Du, L. Chen, C. Xu, G. Liu, P. W. Lee, Y. Tang, In silico assessment of chemical biodegradability, J. Chem. Inf. Model. 52 (2012) 655–669; https://doi.org/10.1021/ci200622d
- 53. L. Moriguchi, S. Hirono, Q. Liu, I. Nakagome and Y. Matsushita, Simple method of calculating octanol/water partition coefficient, Chem. Pharm. Bull.40 (1992) 127–130.
- 54. T. I. Oprea, J. Gottfries, V. Sherbukhin, P. Svensson and T. C. Kuhler, Chemical information management in drug discovery: optimizing the computational and combinatorial chemistry interfaces, J. Mol. Graph. Model.18 (2000) 512–524; https://doi.org/10.1016/S1093-3263(00)00066-8